Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
- PMID: 28333016
- DOI: 10.1016/j.ijrobp.2017.01.221
Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Abstract
Purpose: To identify risk factors associated with a decline in liver function after stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma.
Methods and materials: Data were analyzed from patients with hepatocellular carcinoma treated on clinical trials of 6-fraction SBRT. Liver toxicity was defined as an increase in Child-Pugh (CP) score ≥2 three months after SBRT. Clinical factors, SBRT details, and liver dose-volume histogram (DVH) parameters were tested for association with toxicity using logistic regression. CP class B patients were analyzed separately.
Results: Among CP class A patients, 101 were evaluable, with a baseline score of A5 (72%) or A6 (28%). Fifty-three percent had portal vein thrombus. The median liver volume was 1286 cc (range, 766-3967 cc), and the median prescribed dose was 36 Gy (range, 27-54 Gy). Toxicity was seen in 26 patients (26%). Thrombus, baseline CP of A6, and lower platelet count were associated with toxicity on univariate analysis, as were several liver DVH-based parameters. Absolute and spared liver volumes were not significant. On multivariate analysis for CP class A patients, significant associations were found for baseline CP score of A6 (odds ratio [OR], 4.85), lower platelet count (OR, 0.90; median, 108 × 109/L vs 150 × 109/L), higher mean liver dose (OR, 1.33; median, 16.9 Gy vs 14.7 Gy), and higher dose to 800 cc of liver (OR, 1.11; median, 14.3 Gy vs 6.0 Gy). With 13 CP-B7 patients included or when dose to 800 cc of liver was replaced with other DVH parameters (eg, dose to 700 or 900 cc of liver) in the multivariate analysis, effective volume and portal vein thrombus were associated with an increased risk.
Conclusions: Baseline CP scores and higher liver doses (eg, mean dose, effective volume, doses to 700-900 cc) were strongly associated with liver function decline 3 months after SBRT. A lower baseline platelet count and portal vein thrombus were also associated with an increased risk.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):577-585. doi: 10.1016/j.ijrobp.2017.11.030. Epub 2017 Nov 27. Int J Radiat Oncol Biol Phys. 2018. PMID: 29413273
-
Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.Pract Radiat Oncol. 2017 Sep-Oct;7(5):e331-e337. doi: 10.1016/j.prro.2017.03.004. Epub 2017 Mar 9. Pract Radiat Oncol. 2017. PMID: 28442242
-
Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):900-909. doi: 10.1016/j.ijrobp.2018.04.011. Epub 2018 Apr 12. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976502 Clinical Trial.
-
Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.J Med Imaging Radiat Oncol. 2021 Jun;65(3):365-373. doi: 10.1111/1754-9485.13184. Epub 2021 Apr 22. J Med Imaging Radiat Oncol. 2021. PMID: 33890425 Review.
-
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029785 Review.
Cited by
-
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma.Liver Cancer. 2023 Oct 1;13(3):265-276. doi: 10.1159/000533425. eCollection 2024 Jun. Liver Cancer. 2023. PMID: 38756147 Free PMC article.
-
Prognostic analysis of radiation-induced liver damage following carbon-ion radiotherapy for hepatocellular carcinoma.Radiat Oncol. 2024 Apr 22;19(1):51. doi: 10.1186/s13014-024-02444-3. Radiat Oncol. 2024. PMID: 38649902 Free PMC article.
-
Biochemical Safety of SBRT to Multiple Intrahepatic Lesions for Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2024 Mar 5;11:443-454. doi: 10.2147/JHC.S447025. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38476559 Free PMC article.
-
Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy.Indian J Med Res. 2024 Feb 1;159(2):232-240. doi: 10.4103/ijmr.ijmr_1171_21. Epub 2024 Apr 4. Indian J Med Res. 2024. PMID: 38442296 Free PMC article.
-
Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC) With Single Photon Emission Computed Tomography (SPECT) Functional Treatment Planning in Patients With Advanced Hepatic Cirrhosis.Adv Radiat Oncol. 2023 Sep 1;9(2):101367. doi: 10.1016/j.adro.2023.101367. eCollection 2024 Feb. Adv Radiat Oncol. 2023. PMID: 38405302 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous